SEQUA Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.…
Industry Peers
Medical DevicesKey Statistics
About Sequana Medical (EBR: SEQUA)
›
Sequana Medical (EBR: SEQUA) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 48 employees.
The shares were at 0.6110 EUR on 18 November 2026, down 6.4% over 52 weeks. Its 52-week range is 0.4600 EUR to 0.8650 EUR: the price is 29.4% below the high and 32.8% above the low.
Its market capitalisation is 47.76M EUR.
Sequana Medical reports return on equity of 100.6% and an operating margin of 0.0%.
Its debt exceeds its cash by 34.09M EUR. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.